Distribution of the Major Cytochrome P450 (CYP) 2C9 Genetic Variants in a Saudi Population

被引：15

作者：

Mirghani, Rajaa A. ^{[1
]}

Chowdhary, Gulnaz ^{[1
]}

Elghazali, Gehad ^{[1
,2
,3
]}

机构：

[1] King Saud Bin Abdulaziz Univ Hlth Sci, Fac Med, King Fahad Med City, Riyadh 11393, Saudi Arabia

[2] King Fahad Med City, Dept Immunol, Riyadh, Saudi Arabia

[3] Univ Shendi, Fac Med & Hlth Sci, Shendi, Sudan

来源：

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2011年 / 109卷 / 02期

关键词：

MUTANT ALLELES; P4502C9; POLYMORPHISMS; CYP2C19; PHARMACOKINETICS; FREQUENCIES; OXIDATION; GENOTYPES; LOSARTAN; WARFARIN;

D O I：

10.1111/j.1742-7843.2011.00692.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cytochrome P450 (CYP) 2C9 is responsible for the metabolism of a number of widely used drugs such as oral anticoagulants, oral antidiabetics and non-steroidal anti-inflammatory drugs. The CYP2C9 is a genetically polymorphic enzyme. The most common allele is CYP2C9*1, while CYP2C9*2 and CYP2C9*3 are the less-frequent variants. The activity of the enzyme encoded by either CYP2C9 *2 or *3 variant is lower compared with that of the CYP2C9*1. The metabolism of most of the CYP2C9 substrates decreases in varying degrees in subjects carrying the CYP2C9 *2 or *3 allele. The aim of this study was to investigate the frequencies of the major variants of the CYP2C9 in Saudi Arabians.

引用

收藏

页码：111 / 114

页数：4

相关论文

共 30 条

[1] Functional impact of CYP2C*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans [J].

Allabi, AC ;

Gala, JL ;

Horsmans, Y ;

Babaoglu, MO ;

Bozkurt, A ;

Heusterspreute, M ;

Yasar, U .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (02) :113-118

[2] Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations [J].

Allabi, AC ;

Gala, JL ;

Desager, JP ;

Heusterspreute, M ;

Horsmans, Y .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (06) :653-657

[3] CYP2C9 genetic variants and losartan oxidation in a Turkish population [J].

Babaoglu, MO ;

Yasar, U ;

Sandberg, M ;

Eliasson, E ;

Dahl, ML ;

Kayaalp, SO ;

Bozkurt, A .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (05) :337-342

[4] The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes [J].

Christensen, M ;

Andersson, K ;

Dalén, P ;

Mirghani, RA ;

Muirhead, GJ ;

Nordmark, A ;

Tybring, G ;

Wahlberg, A ;

Yasar, Ü ;

Bertilsson, L .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (06) :517-528

[5] CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers [J].

Dorado, P ;

Berecz, R ;

Norberto, MJ ;

Yasar, Ü ;

Dahl, ML ;

LLerena, A .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (03) :221-225

[6] Distribution of CYP2C9 and VKORC1 Risk Alleles for Warfarin Sensitivity and Resistance in the Israeli Population [J].

Efrati, Edna ;

Elkin, Hela ;

Sprecher, Eli ;

Krivoy, Norberto .

CURRENT DRUG SAFETY, 2010, 5 (03) :190-193

[7]

EVANS DAP, 1995, PHARMACOGENETICS, V5, P64

[8] Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population [J].

Hamdy, SI ;

Hiratsuka, M ;

Narahara, K ;

El-Enany, M ;

Moursi, N ;

Ahmed, MSE ;

Mizugaki, M .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (06) :596-603

[9] Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs -: Clinical relevance [J].

Kirchheiner, J ;

Roots, I ;

Goldammer, M ;

Rosenkranz, B ;

Brockmöller, J .

CLINICAL PHARMACOKINETICS, 2005, 44 (12) :1209-1225

[10] Clinical consequences of cytochrome P4502C9 polymorphisms [J].

Kirchheiner, J ;

Brockmöller, J .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (01) :1-16